Laura Forgione

Naples, 80131, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Low Impact of Clonal Hematopoiesis on the Determination of RAS Mutations by Cell-Free DNA Testing in Routine Clinical Diagnostics.

Low Impact of Clonal Hematopoiesis on the Determination of RAS Mutations by Cell-Free DNA Testing in Routine Clinical Diagnostics.

Journal: Diagnostics (Basel, Switzerland)

Published: June 09, 2022

Dynamics of RAS/BRAF Mutations in cfDNA from Metastatic Colorectal Carcinoma Patients Treated with Polychemotherapy and Anti-EGFR Monoclonal Antibodies.

Dynamics of RAS/BRAF Mutations in cfDNA from Metastatic Colorectal Carcinoma Patients Treated with Polychemotherapy and Anti-EGFR Monoclonal Antibodies.

Journal: Cancers

Published: December 27, 2021

Genomic alterations in cholangiocarcinoma: clinical significance and relevance to therapy.

Genomic alterations in cholangiocarcinoma: clinical significance and relevance to therapy.

Journal: Exploration of targeted anti-tumor therapy

Published: December 18, 2021

Circulating Tumor DNA Testing Opens New Perspectives in Melanoma Management.

Circulating Tumor DNA Testing Opens New Perspectives in Melanoma Management.

Journal: Cancers

Published: September 15, 2020

Targeted sequencing analysis of cell-free DNA from metastatic non-small-cell lung cancer patients: clinical and biological implications.

Targeted sequencing analysis of cell-free DNA from metastatic non-small-cell lung cancer patients: clinical and biological implications.

Journal: Translational lung cancer research

Published: March 25, 2020

Colorectal cancer genomic biomarkers in the clinical management of patients with metastatic colorectal carcinoma.

Colorectal cancer genomic biomarkers in the clinical management of patients with metastatic colorectal carcinoma.

Journal: Exploration of targeted anti-tumor therapy

Published: January 01, 2020

The role of circulating free DNA in the management of NSCLC.

The role of circulating free DNA in the management of NSCLC.

Journal: Expert review of anticancer therapy

Published: November 22, 2018

RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial.

RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: September 27, 2017

Clinical utility of circulating tumor cells in patients with non-small-cell lung cancer.

Clinical utility of circulating tumor cells in patients with non-small-cell lung cancer.

Journal: Translational lung cancer research

Published: September 15, 2017

Assessment of high-sensitive methods for the detection of EGFR mutations in circulating free tumor DNA from NSCLC patients.

Assessment of high-sensitive methods for the detection of EGFR mutations in circulating free tumor DNA from NSCLC patients.

Journal: Pharmacogenomics

Published: August 08, 2015

EGFR mutations in lung cancer: from tissue testing to liquid biopsy.

EGFR mutations in lung cancer: from tissue testing to liquid biopsy.

Journal: Future oncology (London, England)

Published: June 05, 2015

The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies.

The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies.

Journal: Cancer biology & therapy

Published: September 13, 2013

Showing 1-12 of 12

Last Updated: 09/26/2026